Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review

Nishant Jindal; Aditya Jandial; Arihant Jain; Deepesh Lad; Gaurav Prakash; Alka Khadwal; Ritambhra Nada; Jasmine Sethi; Jasmina Ahluwalia; Pankaj Malhotra

doi:10.1016/j.hemonc.2020.07.001

Citations

388

Views

Abstract

Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.

Cite this Article (APA)

Nishant, J., Aditya, J., Arihant, J., Deepesh, L., Gaurav, P., Alka, K., Ritambhra, N., Jasmine, S., Jasmina, A., Pankaj, M. (2023). Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2020.07.001